Samsrita Labs Limited share price
BSE: SAMSRITA
Key numbers
- Market cap
- ₹ 28.2 Cr
- Current price
- ₹ 12.41
- 52-week high / low
- ₹ 25 / 10
- Stock P/E
- -
- Book value
- ₹ 5.2
- Dividend yield
- 0.00%
- ROCE
- -62.5%
- ROE
- -68.8%
- Debt to equity
- 0.14
- Sales growth (3 yrs)
- 0.0%
- Profit growth (3 yrs)
- -
- 1-year return
- -36.4%
About Samsrita Labs Limited
Samsrita Labs Limited operates as a biopharmaceutical company in India. It offers DNA, RNA, and chromosomal-based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, and prenatal and pre-implantation genetic diagnostics; and quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Sanger and Next Generation Sequencing (NGS), karyotype, and fluorescence in-situ hybridization analysis. The company is also involved in the stem cell research and therapy, including regenerative medicine, bio-artificial organ scaffold development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology for the body organs of the liver, pancreas, neural, cardiac, vascular, renal, and orthopedic systems. In addition, it engages in new drug discovery, targeting therapeutic areas, such as Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular disease, cystinosis, and Huntington's disease. Further, the company provides molecular prognosis and diagnostic services in the areas of cytogenetics, pharmacogenomics, pathology, radiology,…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 |
| Operating profit | -0 | 0 | -3 | -0 | -0 |
| Net profit | -0 | 0 | -3 | -0 | -0 |
| EPS (₹) | - | 0.00 | -1.29 | -0.06 | -0.08 |
Peers in Diagnostics & Research
Data for information only, not investment advice. Prices end of day.